Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Editorial Enquiries – GOLD
Editorial Enquiries – EMJ
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Editorial Enquiries – GOLD
Editorial Enquiries – EMJ
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Precision Medicine in Lung Cancer Treatment
March 2024
Nathan Merrill, University of Michigan, Ann Arbor, USA, presents his work on a precision medicine-based platform, which is used to…
Read more
26th June 2015
Combined Nivolumab and Ipilimumab or Monotherapy Shown Promise in Untreated Melanoma
The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression…
26th June 2015
Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis
Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy…
26th June 2015
Obinutuzumab Doubles Remission Duration in Relapsed, Indolent Non-Hodgkin Lymphoma
Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy…
26th June 2015
Daratumumab Shows Promise in Heavily Treatment-Resistant Multiple Myeloma
A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of…
26th June 2015
New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed CLL
An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients…
2nd June 2015
Genomic Marker Predicts Anti-PD-1 Response in Several Cancers
A phase II study identified the first genomic marker – mismatch repair (MMR) deficiency – to predict response to the anti-PD-1 antibody pembrolizumab…
2nd June 2015
Nivolumab Extends Survival for Patients With the Most Common Lung Cancer
Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small…
2nd June 2015
An introduction to ASCO 2015 by the 2014-15 president, Peter Paul Yu, MD, FACP, FASCO
Peter Paul Yu, MD, FACP, FASCO introduces ASCO 2015 and the conference themes – how to utilise data, to transform it into learning to impact patient care.
Loading posts...
« Previous
1
…
39
40
41
42
43
…
45
Next »